文献速递关节外科

Frank Stinchfield奖:识别金属对金属全髋关节置换术后假瘤发生的高危基因型

Frank Stinchfield Award: Identification of the At-risk Genotype for Development of Pseudotumors Around Metal-on-metal THAs.
PubMed 文献 · Clin Orthop Relat Res · 2018-01-01

该病例对照研究纳入26例因症状性不良局部组织反应(ALTR)行翻修术的原发性金属对金属(MoM)全髋关节置换术(THA)患者和28例无症状对照,发现风险基因型(HLA II类等位基因)携带者翻修风险增加(OR 6.1,95%CI 1.5-25.4,P=0.01),提示HLA II类基因变异可能与假瘤形成相关。

要点

  • 风险基因型在全体队列中占30%(16/54)。
  • 校正性别后,风险基因型携带者翻修风险为无风险基因型者的6.1倍(95%CI 1.5-25.4,P=0.01)。
  • 女性中风险基因型特异度为1.0(95%CI 0.5-1.0,P=0.03),男性为0.8(95%CI 0.6-0.9,P<0.01)。

核心结论

  • 在原发性MoM THA患者中,HLA II类基因座等位基因变异可能是与假瘤形成后需翻修手术相关的强独立风险因素。

研究设计与样本

  • 病例对照研究,纳入2005至2008年间接受大直径假体原发性MoM THA且随访至少5年的患者,26例因症状性ALTR行翻修术,28例随机选取的无ALTR证据的无症状对照。

主要发现

  • 从初次MoM THA至症状性翻修的平均时间为5.5年(范围1-10年)。
  • 风险基因型在全体队列中的患病率为30%(16/54)。
  • 校正性别后,风险基因型携带者翻修风险为无风险基因型者的6.1倍(95%CI 1.5-25.4,P=0.01)。
  • 女性中风险基因型特异度为1.0(95%CI 0.5-1.0,P=0.03),男性为0.8(95%CI 0.6-0.9,P<0.01)。

关键数值与推荐

  • 风险基因型携带者翻修风险为无风险基因型者的6.1倍(95%CI 1.5-25.4,P=0.01)。
  • 女性中风险基因型特异度为1.0(95%CI 0.5-1.0,P=0.03),男性为0.8(95%CI 0.6-0.9,P<0.01)。

临床怎么用

  • 作者认为该发现提示HLA II类基因座等位基因变异可能是MoM THA后假瘤形成需翻修的强独立风险因素。
  • 作者指出鉴于该研究的假设生成性质,需确证性前瞻性临床研究进一步阐明该关联并探索靶向基因筛查在该特定人群中的临床效用。

局限性

  • 作者指出该研究为假设生成性质,需确证性前瞻性临床研究进一步阐明该关联并探索靶向基因筛查的临床效用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Once touted as the future of hip arthroplasty, metal-on-metal (MoM) bearing surfaces have fallen sharply from favor with the emergence of a strong body of evidence demonstrating unacceptably high premature implant failure rates. The previously unpredictable development of adverse local tissue reactions (ALTRs) has been a substantive contributor to this. Although the underlying pathophysiology of these so-called "pseudotumors" is now well understood, the fundamental predisposing patient risk factors have remained elusive. QUESTIONS/PURPOSES: The aim of this research, as a clinical-genotype correlation analysis, was to identify specific alleles (genes) associated with the development of ALTRs in patients with in situ MoM THAs. METHODS: A case-control study of patients who received a large-head, primary MoM THA between 2005 and 2008 was performed with a minimum followup of 5 years. Twenty-six patients who had undergone revision of a primary MoM THA secondary to symptomatic ALTRs were recruited. The mean timeframe from primary MoM THA to symptomatic revision was 5.5 years (range, 1-10 years). Twenty-eight control subjects were randomly selected asymptomatic patients with no evidence of ALTRs on protocol-specific screening. Baseline demographics and high-resolution genotype (human leukocyte antigen [HLA] Class II) were collected for all patients. Cohorts were similar with respect to age at the time of primary MoM THA (mean, 54.8 versus 54.9 years, p = 0.95) and serum cobalt (mean, 5.5 versus 8.5 μg/L, p = 0.09) and chromium concentrations (mean, 2.9 versus 4.2 μg/L, p = 0.27). The association between genotype and revision surgery secondary to ALTRs was determined with gender as a covariate. RESULTS: The prevalence of the risk genotype was 30% (16 of 54) among the entire cohort. Adjusting for sex, the odds of revision were 6.1 times greater among patients with the risk genotype present than among patients without (95% confidence interval [CI], 1.5-25.4; p = 0.01). Among females, the specificity of the risk genotype was 1.0 (95% CIexact, 0.5-1.0; pexact = 0.03), and for males, it was 0.8 (95% CIexact, 0.6-0.9; pexact < 0.01). CONCLUSIONS: The findings of this study suggest that, among patients with a primary MoM THA, allelic variation within the HLA Class II loci may be a strong, independent risk factor associated with the need for subsequent revision surgery secondary to pseudotumor formation. CLINICAL RELEVANCE: Given the hypothesis-generating nature of this novel undertaking, confirmatory prospective clinical studies are required to further elucidate this correlation and to explore the clinical utility of targeted genetic screening in this specific population. This research may, however, represent a key missing piece in the puzzle that is metal ion-induced pseudotumor formation.

来源:Clin Orthop Relat Res,查看原文。版权归原作者所有。

引用

  1. Kilb BKJ, Kurmis AP, Parry M, et al. Frank Stinchfield Award: Identification of the At-risk Genotype for Development of Pseudotumors Around Metal-on-metal THAs. Clin Orthop Relat Res. 2018. PMID: 29529651. doi:10.1007/s11999.0000000000000028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。